✦ LIBER ✦

BACILLUS CALMETTE-GUERIN VERSUS EPIRUBICIN FOR PRIMARY, SECONDARY OR CONCURRENT CARCINOMA IN SITU OF THE BLADDER: RESULTS OF A EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER—GENITO-URINARY GROUP PHASE III TRIAL (30906)

✍ Scribed by DEREIJKE, T; KURTH, K; SYLVESTER, R; HALL, R; BRAUSI, M; VANDEBEEK, K; LANDSOGHT, K; CARPENTIER, P

Book ID: 121908087
Publisher: Lippincott Williams and Wilkins
Year: 2005
Tongue: English
Weight: 86 KB
Volume: 173
Category: Article
ISSN: 0022-5347
DOI: 10.1097/01.ju.0000150425.09317.67

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

RE: BACILLUS CALMETTE-GUERIN VERSUS EPIR

RE: BACILLUS CALMETTE-GUERIN VERSUS EPIRUBICIN FOR PRIMARY, SECONDARY OR CONCURRENT CARCINOMA IN SITU OF THE BLADDER: RESULTS OF A EUROPEAN ORGANIZATION FOR THE RESEARCH AND TREATMENT OF CANCER–GENITO-URINARY GROUP PHASE III TRIAL (30906)

✍ Mehraban, Darab; Esfahani, Fatemeh 📂 Article 📅 2005 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 135 KB

INTRAVESICAL INSTILLATION OF EPIRUBICIN,

INTRAVESICAL INSTILLATION OF EPIRUBICIN, BACILLUS CALMETTE-GUERIN AND BACILLUS CALMETTE-GUERIN PLUS ISONIAZID FOR INTERMEDIATE AND HIGH RISK TA, T1 PAPILLARY CARCINOMA OF THE BLADDER: A EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER GENITO-URINARY GROUP RANDOMIZED PHASE III TRIAL

✍ VAN DER MEIJDEN, ADRIAN P.M.; BRAUSI, MAURIZIO; ZAMBON, VICTOR; KIRKELS, WIM; DE 📂 Article 📅 2001 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 140 KB

Maintenance Bacillus Calmette-Guerin for

Maintenance Bacillus Calmette-Guerin for Ta T1 Bladder Tumors Is Not Associated with Increased Toxicity: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

✍ Adrian P.M. van der Meijden; Richard J. Sylvester; Wim Oosterlinck; Wolfgang Hoe 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 105 KB

The Side Effects of Bacillus Calmette-Gu

The Side Effects of Bacillus Calmette-Guerin in the Treatment of Ta T1 Bladder Cancer Do Not Predict its Efficacy: Results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial

✍ Richard J. Sylvester; Adrian P.M. van der Meijden; Wim Oosterlinck; Wolfgang Hoe 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 152 KB

2–45 Breast-Conserving Treatment With or

2–45 Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma-In-Situ: Ten-Year Results of European Organisation for Research and Treatment of Cancer Randomized Phase III Trial 10853—A Study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group

✍ Wong, J.S. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Commentary on “International phase III t

Commentary on “International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: Long-term results of the BA06 30894 trial.” Griffiths G, Hall R, Sylvester R, Raghavan D, Parmar MK, and the International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder; Norwegian Bladder Cancer Study Group; Club Urologico Espanol de Tratamiento Oncologico Group. Medical Research Council Clinical Trials Unit, London, United Kingdom: J Clin Oncol 2011;29:2171–7

✍ H. Barton Grossman 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 89 KB